Vimgreen Pharma Concludes Enrollment in phase 2 Trial of VG081821AC

Vimgreen Pharmaceuticals, a research-based pharmaceutical company specializing in adenosine signaling modulation, shared that they have finished enrolling participants in a phase 2 clinical trial for VG081821AC, a new drug for early-to-mid stage Parkinson's disease that is an A2AR antagonist and inverse agonist. 150 individuals have been signed up and randomly assigned to either a high-dose VG081821 group, a low-dose VG081821 group, or a placebo group in equal numbers.

The multicenter, randomized, placebo-controlled, double-blind clinical study will last 12 weeks and aims to assess the safety and effectiveness of VG081821 as the sole treatment for patients with early-to-mid stage PD. The main focus was on the variation in movement disorder society-unified Parkinson’s disease rating scale (MDS-UPDRS) part III score between VG081821 and placebo during the 12-week treatment period.

Treatment options for Parkinson's disease patients primarily rely on strategies involving dopamine replacement, including using L-Dopa (the preferred option), dopamine agonists, MAO-B inhibitors, and COMT inhibitors. These medications either boost dopamine levels or imitate dopamine's effects. Nevertheless, even though L-Dopa effectively decreases the motor symptoms of PD, the development of motor complications (such as wearing-off, ON-OFF phenomenon, dyskinesia) is almost unavoidable with prolonged use. The limitation of dopamine replacement therapy is widely recognized. Moreover, the existing treatments for PD only address symptoms. These treatments do not have the capability to inhibit the advancement of PD.